ArticleTransplantation2018
Tofacitinib Halts Progression of Graft Dysfunction in a Rat Model of Mixed Cellular and Humoral Rejection.
Article in Transplantation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 18 citations in OpenAlex.
- Differences on the Natural Course of Chronic Kidney Disease Progression, Induced by 5/6 Renal Ablation Model in Three Different Rat Stains: Wistar, Lewis, and Fischer 344.Life (Basel, Switzerland) · 2026Article
- Enhanced Kidney Targeting and Distribution of Tubuloids During Normothermic Perfusion.Transplant international : official journal of the European Society for Organ Transplantation · 2025Article
- NK Cells: Not Just Followers But Also Initiators of Chronic Vascular Rejection.Transplant international : official journal of the European Society for Organ Transplantation · 2024Review
- JAKinibs prevent persistent, IFNγ-autonomous endothelial cell inflammation and immunogenicity.American journal of physiology. Cell physiology · 2023Article
- Extracorporeal Photopheresis Improves Graft Survival in a Full-Mismatch Rat Model of Kidney Transplantation.Transplant international : official journal of the European Society for Organ Transplantation · 2023Article
- Jakinibs of All Trades: Inhibiting Cytokine Signaling in Immune-Mediated Pathologies.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Modeling patients as decision making units: evaluating the efficiency of kidney transplantation through data envelopment analysis.Health care management science · 2021Article
- Liver transplant immunosuppression during the covid-19 pandemic.Gastroenterologia y hepatologia · 2020Review
- Nephroprotective Potential of Mesenchymal Stromal Cells and Their Extracellular Vesicles in a Murine Model of Chronic Cyclosporine Nephrotoxicity.Frontiers in cell and developmental biology · 2020Article
- Impact of Mesenchymal Stromal Cells and Their Extracellular Vesicles in a Rat Model of Kidney Rejection.Frontiers in cell and developmental biology · 2020Article
- Profile of Tofacitinib in the Treatment of Ulcerative Colitis: An Evidence-Based Review of Recent Data.Drug design, development and therapy · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe progression from acute to chronic antibody-mediated rejection in kidney transplant recipients is usually not prevented by current therapeutic options. Here, we investigated whether the use of tofacitinib (TOFA), a Janus kinase 3 inhibitor, was capable of preventing the progression of allograft dysfunction in a Fisher-to-Lewis rat model of kidney transplantation.
methodsRats were treated from the third week after transplantation to allow the development of rejection. Treatment was based on cyclosporin A, rapamycin or TOFA. Renal function was assessed at 1, 4, 8, and 12 weeks after transplantation, whereas rat survival, histological lesions, and infiltrating lymphocytes were analyzed at 12 weeks.
resultsTofacitinib prolonged graft survival, preserved tubular and glomerular structures and reduced humoral damage characterized by C4d deposition. Tofacitinib was able to reduce donor-specific antibodies. In addition, T and natural killer cell graft infiltration was reduced in TOFA-treated rats. Although rapamycin-treated rats also showed prolonged graft survival, glomerular structures were more affected. Moreover, only TOFA treatment reduced the presence of T, B and natural killer cells in splenic parenchyma.
conclusionsTofacitinib is able to reduce the immune response generated in a rat model of kidney graft rejection, providing prolonged graft and recipient survival, better graft function, and less histological lesions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.